Comparison of the Analgesic Efficacy of Transversalis Fascia Plane Block and Posterior Quadratus Lumborum Block in Pediatric Patient Undergoing Orchiopexy: A Prospective Observational Study

NCT07286799 | Completed

• 1 other identifier: E-48670771-514.9900
• Study Type: observational
• Target: 54
• Locations: 1 country
• Sites: 1

Brief Summary

It was planned to compare the analgesic efficacy of the transversalis fascia plane block and the posterior quadratus lumborum block in children aged 1 to 7 years undergoing orchiopexy, by evaluating their FLACC scores and the time to first postoperative analgesic requirement.

Conditions

Quadratus Lumborum Block; Pain Management; Orchiopexy; Transversalis Fascia Plane Block

Keywords

Transversalis fascia plane block; Quadratus lumborum block; Orchiopexy; Pain management

Outcome Measures

Primary Outcomes (1)

• Time to First Analgesic Requirement After Surgery

  The time elapsed from the end of surgery to the administration of the first rescue analgesic.

  First 24 hours postoperatively

Secondary Outcomes (1)

• FLACC Pain Scores at Specified Time Intervals

  First 24 hours postoperatively

Study Arms (2)

Children aged 1-7 years undergoing orchiopexy who received a transversalis fascia plane block.

Children aged 1-7 years undergoing orchiopexy who received a transversalis fascia plane block.

Children Aged 1-7 Years Undergoing Orchiopexy Who Received a Posterior Quadratus Lumborum Block

Children Aged 1-7 Years Undergoing Orchiopexy Who Received a Posterior Quadratus Lumborum Block

Eligibility Criteria

• Age: 1 Year - 7 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Child (0-17)
• Sampling Method: Non-Probability Sample

Study Population

Children aged 1 to 7 years with ASA physical status I-II undergoing unilateral orchiopexy surgery.

You may qualify if:

• Children aged 1 to 7 years with ASA physical status I-II undergoing unilateral orchiopexy surgery.

You may not qualify if:

• ASA physical status ≥ III
• History of prematurity (gestational age \< 37 weeks) Known coagulation disorders or bleeding tendency
• Infection, inflammation, or skin lesion at the injection site
• Known neurological or neuromuscular diseases
• Presence of significant cardiac or pulmonary disease (e.g., congenital heart disease, active asthma)
• Hepatic or renal dysfunction
• Known allergy or hypersensitivity to local anesthetics (e.g., bupivacaine, lidocaine)
• Developmental delay or cognitive impairment that prevents accurate pain assessment
• Use of additional regional analgesia techniques (e.g., caudal block) during surgery
• Lack of parental consent for participation in the study

Sponsors & Collaborators

• Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization: lead

Study Sites (1)

Prof. Dr. Cemil Taşcıoğlu Şehir Hastanesi

Istanbul, Şişli, 34384, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Agnosia

Condition Hierarchy (Ancestors)

Perceptual Disorders; Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident Doctor

Study Record Dates

• First Submitted: December 3, 2025
• First Posted: December 16, 2025
• Study Start: May 1, 2025
• Primary Completion: November 1, 2025
• Study Completion: November 1, 2025
• Last Updated: December 31, 2025

Record last verified: 2025-12

Locations

TU (1)